Loading…
Lobbying Income
$408.1M
Filings
10,730
Unique Clients
151
Active Period
1999–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. Issues relating to the Credit Card Competition Act. S. 3623 & H.R. 7035. S. 394. PL 119-27 Guiding and Establishing National Innovation for US Stablecoin (GENIUS) Act. H.R. 3633, the Digital Asset Market Clarity (CLARITY) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3633
Issues relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. Issues relating to the Credit Card Competition Act. S. 3623 & H.R. 7035. S. 394. PL 119-27 Guiding and Establishing National Innovation for US Stablecoin (GENIUS) Act. H.R. 3633, the Digital Asset Market Clarity (CLARITY) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7035
Issues relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. Issues relating to the Credit Card Competition Act. S. 3623 & H.R. 7035. S. 394. PL 119-27 Guiding and Establishing National Innovation for US Stablecoin (GENIUS) Act. H.R. 3633, the Digital Asset Market Clarity (CLARITY) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 3623
Issues relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. Issues relating to the Credit Card Competition Act. S. 3623 & H.R. 7035. S. 394. PL 119-27 Guiding and Establishing National Innovation for US Stablecoin (GENIUS) Act. H.R. 3633, the Digital Asset Market Clarity (CLARITY) Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 394
Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.
Client expense: — · Firm income: $60,000
Matched citations: HR6509
Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX.
Client expense: — · Firm income: $60,000
Matched citations: S3794
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to TrumpRX.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: — · Firm income: $50,000
Matched citations: S. 832
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to TrumpRX.
Client expense: — · Firm income: $50,000
Matched citations: S. 832
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2005
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2902
DME Scammer Prevention Act of 2026
2026 · third_quarter · Client: OWENS & MINOR, INC.
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 8871
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: S. 1406
Competitive Bidding Relief Act
2026 · third_quarter · Client: OWENS & MINOR, INC.
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: S. 2951
Issues related to access to home medical equipment and related reimbursement (i.e., "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4037) and "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); "DME Scammer Prevention (H.R. 8871)"; promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.
Client expense: — · Firm income: $80,000
Matched citations: S. 4037
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Client: ORGANON
Issues related to prevention of unintended pregnancy and access to contraceptives. Increasing access to fertility services. H.R. 1, One Big Beautiful Bill Act, issues related to CHC funding.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Client: NOVOCURE INC.
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
2026 · third_quarter · Client: NOVOCURE INC.
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Client: NOVOCURE INC.
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
Client expense: — · Firm income: $60,000
Matched citations: S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
2026 · third_quarter · Client: NOVOCURE INC.
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.
Client expense: — · Firm income: $60,000
Matched citations: S. 1717
Stealth Bot Prohibition Act
2026 · third_quarter · Client: NEWS MEDIA ALLIANCE
Digital news content and publishing; antitrust issues impacting digital news publishers. Artificial Intelligence policies. Stealth Bot Prohibition Act (H.R. 9915).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 9915
Digital Asset Market Clarity Act
2026 · third_quarter · Client: JPMORGAN CHASE HOLDINGS, LLC
Issues impacting banking policy, including those relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to financial literacy; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. S. 1582. Issues related to implementation of section 1033 of the Dodd Frank Act. Issues related to H.R. 3633, the CLARITY Act and S.1582, the GENIUS Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3633
Issues impacting banking policy, including those relating to interchange fees on electronic payments; credit card interchange proposals; issues relating to financial literacy; issues relating to payment innovation and card technology; issues related to payment card security; issues relating to Data Use and Privacy. S. 1582. Issues related to implementation of section 1033 of the Dodd Frank Act. Issues related to H.R. 3633, the CLARITY Act and S.1582, the GENIUS Act.
Client expense: — · Firm income: $50,000
Matched citations: S. 1582, S.1582
Recycling Infrastructure and Accessibility Act of 2025
2026 · third_quarter · Client: INTERNATIONAL BOTTLED WATER ASSOCIATION
H.R. 2145 - Recycling Infrastructure and Accessibility Act (RIAA).
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2145
Source: Senate LDA